Belite Bio, Inc American Depositary Shares (BLTE)
Belite Bio, Inc American Depositary Shares (BLTE) is listed on Nasdaq, where it has traded since April 29, 2022.
- Listed On
- Nasdaq
- Listed Since
- April 29, 2022
- Employees
- 41
- Market Cap
- $6.0B
About Belite Bio, Inc American Depositary Shares
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 81 institutions reported holding BLTE, with 9.5 million shares worth $1.4 billion in aggregate. The largest reported holder was Darwin Global Management, Ltd, with 3.1 million shares worth $456.6 million. Of the 5 largest holders listed below, 1 opened a new position in BLTE, 2 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Darwin Global Management, Ltd | 3,077,219 | $457M | Added 0.65% |
| Paradigm Biocapital Advisors | 1,232,877 | $190M | Added 10.59% |
| Rtw Investments | 715,332 | $110M | Unchanged |
| Millennium Management | 494,564 | $76M | Reduced 13.25% |
| Maverick Capital | 396,311 | $61M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is BLTE?
Belite Bio, Inc American Depositary Shares (BLTE) is listed on Nasdaq, where it has traded since April 29, 2022.
Who are the largest institutional holders of BLTE?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of BLTE were Darwin Global Management, Ltd, Paradigm Biocapital Advisors and Rtw Investments.
How many institutions own BLTE?
81 institutions reported a position in BLTE for the quarter ended June 30, 2026, worth $1.4 billion in total.
Did institutions buy or sell BLTE last quarter?
Of the 5 largest reported holders, 1 opened a new position in BLTE, 2 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for BLTE.
Every reported institutional holder, plus insider and congressional trades in BLTE, on SentiSense.